Get started
Work

MPN-548 Phase I/II Study of the Activin Receptor-Like Kinase 2 (ALK2) Inhibitor Zilurgisertib (INCB000928, LIMBER-104) as Monotherapy or With Ruxolitinib in Patients With Anemia Due to Myelofibrosis

Year: 2023
Type: conference-abstract
DOI: 10.1016/s2152-2650(23)01254-5
Authors: Prithviraj Bose, Sanjay Mohan, Stephen Oh, Jason Gotlib, Ellen Ritchie, Taizo Shimomura, Haris Ali, Francoise Boyer, Paola Guglielmelli, Anthony Hunter, Betty Lamothe, Yi Cui, Francis Seguy, Amanda McBride, Francesca Palandri, Masahiro Takeuchi, Jean-Jacques Kiladjian
Institutions: The University of Texas MD Anderson Cancer Center, Vanderbilt University, GlaxoSmithKline (United States), Vanderbilt-Ingram Cancer Center, Washington University in St. Louis, Alvin J. Siteman Cancer Center, Stanford Cancer Institute, Analysis Group (United States), Weill Cornell Medicine, Kumamoto Shinto General Hospital, City Of Hope National Medical Center, City of Hope, Centre Hospitalier Universitaire d'Angers, University of Florence, Emory University, Winship Cancer Institute, Incyte (United States), Istituto di Ematologia di Bologna, Chiba Cancer Center, Université Paris Cité, Assistance Publique – Hôpitaux de Paris, Hôpital Saint-Louis
Language: English
Field: Medicine
Open Access status: closed
OpenAlex ID: W4386271014
Cites:
Cited by:
Related to: 10